BFLY vs ONC
Butterfly Network, Inc. vs BeOne Medicines AG — AI-powered side-by-side comparison
BFLY
Butterfly Network, Inc.
67
Buy
VS
ONC
BeOne Medicines AG
64
Buy
| Metric | BFLY | ONC |
|---|
| AI Score |
67
|
64
|
| Price |
$9.36
|
$359.20
|
| P/E Ratio |
-32.38×
|
29.70×
|
| ROE |
-39.3%
|
6.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
51.1%
|
87.8%
|
| Debt / Equity |
0.10×
|
0.22×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
66.4
|
84.1
|
| Beta |
2.084
|
0.5
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for BFLY versus ONC.
BFLY leads by 3 points.
BFLY scores 67/100 (Buy) versus ONC at 64/100 (Buy).
BFLY Committee View
67% agreement
6 analysts
The primary driver is revenue growing 28.1% yoy -- genuine top-line momentum. The main limiting factor is roe of only -38.4% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 28.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -38.4% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 52.6% signals elevated volatility — Risk
ONC Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 36.2% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 86.0 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 36.2% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 86.0 is expensive by classic value standards — Value
- Price-to-book of 8.7x prices in significant intangible value — Value
- RSI at 84 is in overbought territory — Technical